Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00192322 · ClinicalTrials.gov registry record · Phase 2
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
NCT00192322 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 173 participants.
The verdict
NCT00192322, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
Study Summary
To perform a variety of assays on blood, nasal washes, and cells obtained from healthy children for the purposes of further investigation of immune responses generated by influenza virus vaccine, trivalent, types A and B, live, cold-adapted (liquid CAIV-T; Wyeth Lederle Vaccines, Marietta, PA). • To assess nasal swab specimens to detect vaccine virus shedding.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL TIV
- BIOLOGICAL CAIV-T 10^7
- BIOLOGICAL CAIVT 10^5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2001-09 |
| Est. Completion | 2001-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00192322
The ClinicalTrials.gov registry entry for NCT00192322 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00192322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00192322 about?
NCT00192322 is a clinical study titled "Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children". To perform a variety of assays on blood, nasal washes, and cells obtained from healthy children for the purposes of further investigation of immune responses generated by influenza virus vaccine, trivalent, types A and B, live, cold-adapted (liquid CAIV-T; Wyeth Lederle Vaccines, Marietta, PA). • T...
What is the current status of trial NCT00192322?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2001-09. Estimated completion is 2001-12.
What interventions are being tested in trial NCT00192322?
The interventions under investigation include: Placebo (BIOLOGICAL), TIV (BIOLOGICAL), CAIV-T 10^7 (BIOLOGICAL), CAIVT 10^5 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00192322?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.